For the full-year 2023, the Company anticipates double-digit Galafold revenue growth of 12-17% at constant exchange rates, CER. Growth is expected to be driven by continued underlying demand from both switch and treatment-naive patients, geographic expansion, continued diagnosis of new Fabry patients, and commercial execution across all major markets, including the U.S., EU, U.K., and Japan.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FOLD:
- Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Amicus receives positive CHMP opinion for Pombiliti for LOPD
- Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
- Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
